Trends in Early Outpatient Drug Therapy in Pediatric Inflammatory Bowel Disease in Finland: A Nationwide Register-Based Study in 1999–2009
Table 1
Pediatric patients with Crohn’s disease with purchases of disease modifying drugs for inflammatory bowel disease during the first 12 months by three different periods between the years 1999 and 2009.
Medication
1999–2009
1999–2005
2006-2007
2008-2009
valuea
ATC-code
(%)
(%)
(%)
(%)
for linear trend
5-ASA (acting locally)
A07EC02
25
(13.3)
7
(18.4)
8
(15.1)
10
(10.3)
0.222
5-ASA (for systemic use)
A07EC02
174
(92.6)
32
(84.2)
49
(92.5)
93
(95.9)
0.040
Sulfasalazine
A07EC01
3
(1.6)
1
(2.6)
0
2
(2.1)
0.879
Corticosteroids (acting locally)
A07EA02; A07EA06
19
(10.1)
8
(21.1)
5
(9.4)
6
(6.2)
0.059
Corticosteroids (for systemic use)
H02AB06; -02; -04; -07; -09; A07EA06
137
(72.9)
29
(76.3)
36
(67.9)
72
(74.2)
0.802b
Metronidazole
P01AB01
74
(39.4)
16
(42.1)
15
(28.3)
43
(44.3)
0.414
Ciprofloxacin
J01MA02
36
(19.1)
5
(13.2)
7
(13.2)
24
(24.7)
0.131
Azathioprine
L04AX01
80
(42.6)
12
(31.6)
19
(35.8)
49
(50.5)
0.030
Methotrexate
L04AX03; L01BA01
6
(3.2)
2
(5.3)
0
4
(4.1)
0.947
aAdjusted for age. bCorticosteroids were analyzed periods 1999–2005 versus 2008-2009 (nonlinear trend over all three periods) as between the years 2006 and 2007 prednisolon 5 mg tablets were not reimbursed in Finland and, thus, a portion of data was not available.
